BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

This study tests a CAR-T cell therapy — immune cells engineered to target two proteins, BCMA and CD19 — as a treatment for serious autoimmune diseases that have not responded to multiple other treatments. These include lupus, Sjögren's syndrome, inflammatory muscle disease, and others. **You may be eligible if...** - You are 18–65 years old and weigh at least 45 kg - You have a confirmed diagnosis of a qualifying autoimmune disease (such as lupus, Sjögren's syndrome, systemic sclerosis, or others) - You have tried and failed multiple standard treatments including steroids and immune-suppressing drugs **You may NOT be eligible if...** - You have an active serious infection - You have a history of heart failure or significant cardiac issues - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.